Pramipexole Dihydrochloride Tablets
GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.
Subpotent Drug: Out of specification result during stability study in Pramipexole Dihydrochloride Tablets 0.125 mg
Cause type: Wrong potency / content
Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.
Pramipexole Dihydrochloride Tablets 0.125 mg,90-count bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Phamaceuticals Ltd. Baddi Himachal Pradesh, India. NDC 33342-031-10
Compare with the code on your package — it is the most precise check available.
Drug: Pramipexole
From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.
| Product | Strength | Form & route | Labeler | Type |
|---|---|---|---|---|
| Pramipexole dihydrochloride NDC 33342-0031 |
.125 mg/1 | Tablet Oral |
Macleods Pharmaceuticals Limited | Rx |
Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.
GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Subpotent Drug
Presence of foreign substance: plastic-like substance.
Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.
Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.